Sector News

Sanofi to exit Bangladesh, reports say, leaving 1,000-plus jobs up in the air

September 19, 2019
Life sciences

Sanofi’s ready to say farewell to Bangladesh, local media reports, despite pleas from government officials to stay put.

After more than 60 years in the country, the drugmaker has notified the Bangladesh Chemical Industries Corporation (BCIC)—which owns about 20% of the company’s local outfit—that it’s planning to exit, the Financial Express reports.

BCIC officials are pressing Sanofi to stay, but the company’s planning to move out for strategic reasons, The Daily Star reports. It could continue supplying medicines to Bangladesh through imports, according to the reports.

As of 2016, Sanofi was the largest pharma company in Bangladesh with more than 1,200 employees there, according to a paper published in the International Journal of Business and Management. It operates a plant in Tongi, according to an SEC filing, and maintains a corporate office in Dhaka.

To make its exit, Sanofi aims to sell its approximately 55% share in the local company. The Bangladeshi government owns the remaining 45%, according to reports.

The move follows GlaxoSmithKline’s Bangladesh exit last year; that company found the market “not sustainable,” according to the Financial Express report.

For Sanofi, the reported exit also comes after the company sold its generics outfit Zentiva to Advent International for $2.2 billion last year. The generics company has a global manufacturing footprint and about 3,000 employees. Earlier this month, Advent bought a Sanofi manufacturing plant in India for $36.5 million.

If Sanofi does in fact exit Bangladesh, it may well be one of the first moves authorized by new Sanofi CEO Paul Hudson. He took up the role at the beginning of this month, replacing Olivier Brandicourt, who retired. During his four-year CEO stint, Brandicourt worked to cut costs and refocus the company around five business units.

A Sanofi representative didn’t immediately comment on the reports.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend